Bristol-Myers Squibb (NYSE: BMY) has announced more news on its immunomodulatory drug Zeposia (ozanimod).
The US pharma major launched the drug in the USA on Monday as a treatment for relapsing forms of multiple sclerosis, having gained a European Commission approval in this disease last week.
Zeposia is not just seen as a multiple sclerosis asset by B-MS, however. It is also in development for additional immune-inflammatory indications, including ulcerative colitis and Crohn’s disease.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze